LBI-1123
THERAPEUTIC AREA
BRAIN CANCER
Indications
Glioblastoma & Metastatic
REGULATORY PATHWAY
First-in-class 3rd generation taxane that crosses the blood brain barrier (BBB) to treat Brain Cancer
TARGET INDICATION
Advanced first in class immediate release second generation taxane based chemotherapy. Incorporate drug resistance & targeting sensitizers
CURRENT DEVELOPMENT STATUS
API synthesis in process, expect first availability in May 2019. Anticipate using Lumnus nano platform to create multiple analogues and rational drug combinations. Development will pause after formulation is complete and until funding and staff resources are secured
NEXT DEVELOPMENT PHASE
Screen multiple candidates, by performing safety & efficacy testing in animals
TIME TO HUMAN BENEFIT
Human trials to begin as soon as 1.5 years from funding & staffing
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire